Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics (NQ: HZNP )

110.63 -0.62 (-0.56%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,600,140
Open 111.20
Bid (Size) 110.40 (3)
Ask (Size) 110.95 (12)
Prev. Close 111.25
Today's Range 110.62 - 111.34
52wk Range 57.84 - 117.49
Shares Outstanding 226,621,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Rule 15 (c) Announcement – Horizon Therapeutics plc
From Horizon Therapeutics plc
Via Business Wire
HORIZON THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Horizon Therapeutics Public Limited Company - HZNP
From Kahn Swick & Foti, LLC
Via Business Wire

Performance

YTD
-2.53%
-2.53%
1 Month
-2.55%
-2.55%
3 Month
+73.32%
+73.32%
6 Month
+33.34%
+33.34%
1 Year
+26.65%
+26.65%

More News

Read More
Rule 17 (b) Announcement – Horizon Therapeutics plc
From Horizon Therapeutics plc
Via Business Wire
Rule 17 (a) Announcement – Horizon Therapeutics plc
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics Touts Positive Data From Mid-Stage Study For Immune System Disorder
Via Benzinga
$1000 Invested In Horizon Therapeutics 5 Years Ago Would Be Worth This Much Today
Via Benzinga
$100 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth This Much Today
Via Benzinga
A Bullish Sign Appears On Horizon Therapeutics's Chart
Via Benzinga
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population; Only Phase 2 Trial to Meet Primary Endpoint in Both Patient Populations
From Horizon Therapeutics plc
Via Business Wire
Rule 2.12 Announcement – Horizon Therapeutics plc
From Horizon Therapeutics plc
Via Business Wire
3 Biotech Companies to Watch in 2023
Via InvestorPlace
5 Top Pharma Stocks of 2022 to Buy for the Long Haul
Via InvestorPlace
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus
From Horizon Therapeutics plc
Via Business Wire
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
5 Most Expensive Health Care Stocks You Should Worry About
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
2 Market-Beating Stocks to Buy in 2023 and Hold Forever
Via The Motley Fool
How Did 2022’s Most Loved Stocks By Analysts Fare?
Via Talk Markets
Universal Health Services, Madrigal Pharmaceuticals And These Overbought Majors In The Healthcare Sector
Via Benzinga
Analyzing Horizon Therapeutics's Short Interest
Via Benzinga
2 No-Brainer Biotech Stocks to Buy Right Now
Via The Motley Fool
Interest Rate Hikes Won't Stop These 2 Cash-Rich Growth Stocks
Via The Motley Fool
UPLIZNA® (inebilizumab-cdon) Approved in Brazil for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
From Horizon Therapeutics plc
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.